News & Press Releases

Sera Prognostics Announces Analytical Validation Study

SALT LAKE CITY, June 26, 2017- Sera Prognostics, Inc., a women’s healthcare company, announced today that its recent analytical study, “Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth” has been published in the June issue of Clinical Mass Spectrometry. The study details a rigorous analytical validation of Sera’s liquid chromatography/mass spectrometry (LC/MS) platform for sensitive later-generation Agilent mass spectrometers. This work confirms Sera’s ability, across instrument generations, to perform accurate analytical measurements required to provide individualized determination of a woman’s risk of spontaneous early delivery through Sera’s groundbreaking PreTRM® test. The PreTRM® test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. MORE >

LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth

BURLINGTON, N.C. - May 23, 2017 - LabCorp® (NYSE: LH) today announced the nationwide availability the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. LabCorp and Sera previously announced their strategic collaboration for LabCorp to be the exclusive U.S. distributor of Sera’s PreTRM test. LabCorp was also a lead investor in Sera’s recently closed Series C financing round. MORE >

Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer

SALT LAKE CITY, May 17, 2017- Sera Prognostics announced today that Nadia F. Altomare has joined the company as chief commercial officer. Ms. Altomare will lead all commercial activities for Sera as the company makes its groundbreaking PreTRM® test available to physicians and patients. The PreTRM test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. MORE >

SERA PROGNOSTICS IS NAMED A 2017 SILVER EDISON AWARD WINNER

New York, NY - April 21, 2017 - The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera Prognostics’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City. MORE >

RESEARCH USING SERA’S PROTEOMIC TECHNOLOGY TO BE PRESENTED AT SOCIETY FOR REPRODUCTIVE INVESTIGATION MEETING

SALT LAKE CITY, March 13, 2017 -- Research using Sera’s innovative proteomic technology platform that revealed evidence for fetal sex differences in placental gene expression as a possible explanation of the association of fetal gender and rate of preterm birth (PTB) will be presented at the 64th Annual Society for Reproductive Investigation March 15-18 in Orlando. MORE >

SERA PROGNOSTICS’ PRETRM® NAMED EDISON AWARDS FINALIST

SALT LAKE CITY, February 9, 2017 - Sera Prognostics has been named a 2017 Award Finalist by the internationally renowned Edison Awards™. These distinguished awards, inspired by Thomas Edison’s persistence and inventiveness, recognize leadership in innovation, creativity and ingenuity in the global economy. MORE >

Research Using Sera’s Proteomic Technology to be Presented at the SMFM 2017 Annual Pregnancy Meeting

January 23, 2017 --- Presentations at SMFM of ongoing research will include evaluating the underlying mechanisms of significant pregnancy complications that result in preterm birth, use of progesterone as an intervention and employing Sera’s innovative proteomic technology platform to predict a woman’s risk for spontaneous and medically-indicated preterm birth. MORE >

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

SALT LAKE CITY, January 10, 2017- LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth. Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. MORE >

Sera Prognostics to Present at 35th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, January 3, 2017 -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference. Dr. Critchfield’s presentation will take place at 7:30 AM PT on Tuesday, January 10th, 2017 in the Elizabethan Room at the Westin St. Francis Hotel in San Francisco, CA. MORE >

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test

December 19, 2016 - Two recent publications show significant clinical utility of assessing preterm birth risk early in pregnancy with novel biomarker tests such as PreTRM®. These reports describe treatment paradigms that use existing interventions with significant potential to improve the health of premature babies, including reduction in mortality rates, as well as a corresponding reduction of direct medical costs to the health care system. MORE >